NEYROBLASTGX

Serial Number 98473509
Registration 7651557
700

Registration Progress

Application Filed
Mar 28, 2024
Under Examination
Approved for Publication
Nov 26, 2024
Published for Opposition
Nov 26, 2024
Registered
Jan 14, 2025

Trademark Image

NEYROBLASTGX

Basic Information

Serial Number
98473509
Registration Number
7651557
Filing Date
March 28, 2024
Registration Date
January 14, 2025
Published for Opposition
November 26, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jan 14, 2025
Registration
Registered
Classes
001 042

Rights Holder

NeyroblastGX LLC

16
Address
26442 Beckman Court
Murrieta, CA 92562

Ownership History

NeyroblastGX LLC

Original Applicant
16
Murrieta, CA

NeyroblastGX LLC

Owner at Publication
16
Murrieta, CA

NeyroblastGX LLC

Original Registrant
16
Murrieta, CA

Legal Representation

Attorney
Ross Epstein

USPTO Deadlines

Next Deadline
1820 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250114)
Due Date
January 14, 2031
Grace Period Ends
July 14, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

9 events
Date Code Type Description Documents
Jan 14, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jan 14, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Nov 26, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Nov 26, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 20, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 18, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 9, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 30, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 28, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 001
Stem cells for scientific and medical research
First Use Anywhere: Feb 14, 2020
First Use in Commerce: Feb 14, 2020
Class 042
Stem cell-based pharmaceutical product development, namely next-generation theranostic products for neurodegenerative and infectious diseases; Product research and development; Scientific research and development.
First Use Anywhere: Feb 14, 2020
First Use in Commerce: Feb 14, 2020

Additional Information

Pseudo Mark
NEYROBLAST GX

Classification

International Classes
001 042